当前位置: X-MOL 学术Stem Cell Res. Ther. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Extracellular vesicles derived from mesenchymal stem cells as a potential therapeutic agent in acute kidney injury (AKI) in felines: review and perspectives
Stem Cell Research & Therapy ( IF 7.5 ) Pub Date : 2021-09-15 , DOI: 10.1186/s13287-021-02573-6
Magdalena M Kraińska 1, 2 , Natalia Pietrzkowska 1 , Eliza Turlej 3 , Li Zongjin 4 , Krzysztof Marycz 1, 3
Affiliation  

Mesenchymal stem cells (MSCs), known from their key role in the regeneration process of tissues, and their abilities to release bioactive factors like extracellular vesicles (EVs) could be considered as a potential, modern tool in the treatment of AKI (acute kidney injury) in both human and veterinary patients. The complex pathophysiology of a renal function disorder (AKI) makes difficult to find a universal therapy, but the treatment strategy is based on MSCs and derived from them, EVs seem to solve this problem. Due to their small size, the ability of the cargo transport, the ease of crossing the barriers and the lack of the ability to proliferate and differentiate, EVs seem to have a significant impact on the development such therapy. Their additional impact associated with their ability to modulate immune response and inflammation process, their strong anti-fibrotic and anti-apoptotic effects and the relation with the releasing of the reactive oxygen species (ROS), that pivotal role in the AKI development is undoubtedly, limits the progress of AKI. Moreover, the availability of EVs from different sources encourages to extend research with using EVs from MSCs in AKI treatment in felines; in that, the possibilities of kidney injuries treatment are still limited to the classical therapies burdened with dangerous side effects. In this review, we underline the significance of the processes, in whose EVs are included during the AKI in order to show the potential benefits of EVs-MSCs-based therapies against AKI in felines.

中文翻译:

源自间充质干细胞的细胞外囊泡作为猫科动物急性肾损伤 (AKI) 的潜在治疗剂:综述和展望

间充质干细胞 (MSC) 因其在组织再生过程中的关键作用以及释放细胞外囊泡 (EV) 等生物活性因子的能力而闻名,可被视为治疗 AKI(急性肾损伤)的潜在现代工具) 在人类和兽医患者中。肾功能障碍 (AKI) 的复杂病理生理学使得很难找到通用疗法,但治疗策略是基于 MSCs 并从中衍生而来,EVs 似乎解决了这个问题。由于其体积小、货物运输能力强、易于穿越障碍以及缺乏增殖和分化能力,电动汽车似乎对此类疗法的发展产生了重大影响。它们的额外影响与其调节免疫反应和炎症过程的能力有关,它们强烈的抗纤维化和抗凋亡作用以及与活性氧 (ROS) 释放的关系,在 AKI 发展中起关键作用,无疑限制了 AKI 的进展。此外,来自不同来源的 EV 的可用性鼓励使用来自 MSC 的 EV 在猫科动物的 AKI 治疗中扩展研究;在这方面,肾损伤治疗的可能性仍然仅限于具有危险副作用的经典疗法。在这篇综述中,我们强调了 AKI 过程中包含 EV 的过程的重要性,以展示基于 EVs-MSCs 的疗法对猫科动物 AKI 的潜在益处。那种在AKI发展中举足轻重的作用,无疑限制了AKI的进步。此外,来自不同来源的 EV 的可用性鼓励使用来自 MSC 的 EV 在猫科动物的 AKI 治疗中扩展研究;在这方面,肾损伤治疗的可能性仍然仅限于具有危险副作用的经典疗法。在这篇综述中,我们强调了 AKI 过程中包含 EV 的过程的重要性,以展示基于 EVs-MSCs 的疗法对猫科动物 AKI 的潜在益处。那个在AKI发展中举足轻重的作用,无疑限制了AKI的进步。此外,来自不同来源的 EV 的可用性鼓励使用来自 MSC 的 EV 在猫科动物的 AKI 治疗中扩展研究;在这方面,肾损伤治疗的可能性仍然仅限于具有危险副作用的经典疗法。在这篇综述中,我们强调了 AKI 过程中包含 EV 的过程的重要性,以展示基于 EVs-MSCs 的疗法对猫科动物 AKI 的潜在益处。肾损伤治疗的可能性仍然仅限于具有危险副作用的经典疗法。在这篇综述中,我们强调了这些过程的重要性,其中 EV 在 AKI 期间被包括在内,以展示基于 EVs-MSCs 的疗法对猫科动物 AKI 的潜在益处。肾损伤治疗的可能性仍然仅限于具有危险副作用的经典疗法。在这篇综述中,我们强调了 AKI 过程中包含 EV 的过程的重要性,以展示基于 EVs-MSCs 的疗法对猫科动物 AKI 的潜在益处。
更新日期:2021-09-16
down
wechat
bug